Successful crizotinib retreatment after crizotinib-induced interstitial lung disease

J Thorac Oncol. 2013 Aug;8(8):e73-4. doi: 10.1097/JTO.0b013e318293dfc1.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics
  • Adenocarcinoma of Lung
  • Crizotinib
  • Female
  • Humans
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Middle Aged
  • Mutation
  • Oncogene Proteins, Fusion / genetics
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrazoles / adverse effects*
  • Pyridines / adverse effects*
  • Retreatment

Substances

  • EML4-ALK fusion protein, human
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib